PRINCETON, N.J., May 15 /PRNewswire-FirstCall/ -- Novo Nordisk today announced the appointments of Pamela Harris, vice president of diabetes sales, managed care and government accounts south/west and Patrick Loustau, vice president of diabetes sales, managed care and government accounts north/midwest. Both will serve as new members of the Novo Nordisk Executive Team, reporting to Martin Soeters, president.
“Both Pam and Patrick are strong, dynamic leaders who will be instrumental in solidifying Novo Nordisk’s premiere status as the U.S. market leader in Changing Diabetes,” said Martin Soeters, president of Novo Nordisk. “It is Novo Nordisk’s progressive approach to accelerating growth through brand strength and its commitment to advancing the health and quality of life for people with diabetes that enable Novo Nordisk to attract and retain industry elite.”
Harris joined Novo Nordisk in December 2005 after 26 years of successful sales leadership in the pharmaceutical industry. Prior to joining Novo Nordisk, she led two sales forces totaling more than 1200 individuals and was responsible for more than $2.4 billion in sales at Novartis Pharmaceuticals Corporation. In addition, she was instrumental in developing the key sales strategies that prompted a significant expansion in her field’s portfolio.
At Novartis, Harris was a member of Executive Women Impacting Novartis and also was honored by the Harlem YWCA as a Black Achiever in Industry. Ms. Harris attributes her success to being results oriented, a driver of team building, and committed to leadership development.
“After my many years of leadership within large pharmaceutical companies, I now am excited to share my insight and experience with a specialized company that has such a strong passion for diabetes,” said Harris. “I look forward to being an instrumental part of Novo Nordisk’s growth and its commitment to providing the best treatment options for people who are living with diabetes.”
Patrick Loustau, a Novo Nordisk executive who has risen quickly during his ten years with the company, has held a variety of positions in marketing and sales in the United States, France, Canada, and Germany. Most recently, he was president of Novo Nordisk Canada Inc. with outstanding 2005 results, establishing the affiliate as an insulin market leader for the first time in ten years. Loustau led all of the company’s functions in Canada and ensured its continued profitability while upholding Novo Nordisk’s commitment to sustainable development.
“I am particularly excited to be joining the U.S. team again at such a critical time in the company’s evolution. We have ambitious goals to expand our presence in the U.S. market as a world leader in diabetes care through exciting, new, innovation-driven programs and a continued dedication to providing quality healthcare to people with diabetes and their families,” said Loustau. “As a long-time veteran of Novo Nordisk, I bring a unique company wide perspective and historical knowledge to the Executive Team and U.S. sales force.”
In their new positions, Harris and Loustau will lead diabetes sales strategies and initiatives, including field sales management, sales promotion, sales force effectiveness, sales training, and strategic sales solution functions in their respective territories.
In the United States, Novo Nordisk has seen tremendous growth within the past few years, more than doubling its workforce since 2000. During that time, the company has heightened its focus on Novo Nordisk’s Triple Bottom Line, which fosters economic success while protecting the well-being of its customers, the community, the environment, and particularly its employees. To this end, the organization’s “My Company” culture promotes a work environment where attention is paid to the human behind the employee, where regular and honest communication is encouraged and valued, and where major accomplishments and small achievements alike are celebrated.
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs approximately 22,000 full- time employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGONovo Nordisk
CONTACT: Media, Susan Jackson, Novo Nordisk, +1-609-919-7776; orInvestors, Mads Veggerby Lausten, Novo Nordisk, +1-609-919-7937
